Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 425
- 试验地点
- 1
- 主要终点
- health-related quality of life (HRQoL)
研究概览
简要总结
The ophthalmology clientele is vulnerable in the context of the coronavirus disease 2019 (COVID-19) pandemic because of their age and comorbidities. Specifically, elderly patients aged 65 and above with glaucoma, age-related macular degeneration, or diabetic retinopathy require regular follow-ups and commonly suffer from additional comorbidities. Further, because of the proximity between the patient and health care personnel during ophthalmological examinations, the risk of infection during visits is significant. The delicate balance between the risk of exposure to COVID-19 and visual loss in delaying cases is a psychological stressor to both patients and clinicians.
A cross-sectional study accumulating the data of 425 patients aged 65 and above with various eye diseases will be conducted. Participants will be presented with a set of online questionnaires designed to collect data on health-related quality of life (HRQOL), vision-related quality of life (VRQOL), depression symptoms, anxiety, sleep quality, community integration, and their experience with tele-consultations. This study can help quantify the collateral impact of the COVID-19 beyond the direct impact of the virus, to improve future quality of care guidelines on non-COVID-19 conditions, and to help plan patient prioritization once restrictions are eased.
详细描述
BACKGROUND AND RATIONALE
COVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Like many healthcare departments, the department ophthalmology presents risk of COVID-19 infection. As a result, the present pandemic has led officials to rethink the management of patient lists and to restrict the patients to be assessed or to be operated based on the urgency of their condition in accordance with ministerial guidelines. A delay in visits might increase the risk of visual loss not only through the delay of necessary care, but also through an increase in non-adherence to treatment. Indeed, patients themselves might decide to interrupt their treatment or postpone their visit for fear of contracting the disease. There is concern not only about compliance to treatment, but also about accessibility issues to medications in high-demand and modifications of treatment protocols.
Elderly people aged 65 and above are commonly afflicted by many eye diseases with vision loss. Furthermore, during times of the COVID-19 pandemic, this population can be vulnerable to possible vision loss due to a delay of care.
As a result, it is being proposed to perform a cross-sectional study using a sample of patients from this population to gather information on follow-up and treatment delays associated with the pandemic's offloading measures as well as any adverse effects on visual acuity that have occurred during the pandemic. The evidence collected from this study could be translated into clinical practices helping to provide recommendations to adjust the response to the COVID-19 pandemic in ophthalmological management.
Visual loss, potentially due to the reasons that were mentioned above, can bring about depressive symptoms and deteriorate the quality of life (QOL). In the proposed study, the investigators have included questionnaires to assess the various stressors brought on during the COVID-19 pandemic such as fear of vision loss, health-related QOL, vision-related QOL, depression and anxiety symptoms, sleep quality, number of ER visits for deterioration of mental health. This evidence base collected from this study could, once again, be translated into clinical practices helping to provide recommendations to adjust the response to the COVID-19 pandemic in ophthalmological management.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with an eye disease by an experienced ophthalmologist.
- •Patients with eye diseases age 65 and above.
- •Be able to provide valid informed consent to participate in the research study.
- •Being able to read and understand English.
- •Having no significant self-reported or a physician diagnosed mental health disorder.
排除标准
- •Inability to provide a valid informed consent.
- •Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.
- •Severe depression as confirmed by a CES-D ≥
- •Having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder).
- •Self-reported substance abuse or dependence within the past 3 months.
- •Having an acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.
- •Having irreversible vision loss that prevents one from completing the questionnaires.
结局指标
主要结局
health-related quality of life (HRQoL)
时间窗: Immediately upon receiving the participant's consent to participate in the study
HRQoL is an essential measure of quality of life related to health; it helps physician identify hidden morbidity in clinical care as well as improves patient-physician communications. HRQoL will be measured using time trade-off questionnaire. It is measured in a scale of 0 to 1, with higher scores indicating a better outcome. This means that 0 indicates poor HRQoL and 1 indicates perfect health.
次要结局
- Visual Function Score(Immediately upon receiving the participant's consent to participate in the study)
- Anxiety(Immediately upon receiving the participant's consent to participate in the study)
- Depression(Immediately upon receiving the participant's consent to participate in the study)
- Sleep Quality(Immediately upon receiving the participant's consent to participate in the study)